ONCY (Oncolytics Biotech) PS Ratio: (As of Jul. 11, 2026)


ONCY Oncolytics Biotech Inc ONCY
28 GF Score
Price $0.89
! 2 Warning Signs
View Full Analysis

What is Oncolytics Biotech PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Oncolytics Biotech's share price is $0.8873. Oncolytics Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Oncolytics Biotech's PS Ratio for today is .

The historical rank and industry rank for Oncolytics Biotech's PS Ratio or its related term are showing as below:

ONCY's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.515
* Ranked among companies with meaningful PS Ratio only.

Oncolytics Biotech's Revenue per Sharefor the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

During the past 13 years, Oncolytics Biotech's highest 3-Year average Revenue per Share Growth Rate was 48.40% per year. The lowest was -4.30% per year. And the median was 22.05% per year.

Back to Basics: PS Ratio


Oncolytics Biotech  (NAS:ONCY) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Oncolytics Biotech PS Ratio Related Terms


Oncolytics Biotech PS Ratio Historical Data

* Premium members only.

The historical data trend for Oncolytics Biotech's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech PS Ratio Chart

Oncolytics Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oncolytics Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ONCY vs VRCA, ENGN, ALDX: PS Ratio Comparison

For the Biotechnology subindustry, Oncolytics Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's PS Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's PS Ratio falls into.


ONCY
28GF Score
Oncolytics Biotech Inc ONCY
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolytics Biotech PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Oncolytics Biotech's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.8873/0
=

Oncolytics Biotech's Share Price of today is $0.8873.
Oncolytics Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Oncolytics Biotech Business Description

Address 4350 Executive Drive, Suite 325, San Diego, CA, USA, 92121
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
28GF Score

Get the complete analysis for ONCY

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.89
Price